BBLG Profile
Bone Biologics Corporation is a specialized medical device company dedicated to advancing bone regeneration technologies with a focus on spinal fusion procedures. The company’s flagship product, NELL-1/DBX, is a combination therapeutic that leverages recombinant human protein to enhance bone regeneration. This osteostimulative recombinant protein is designed to offer targeted control over the bone healing process, aiming to improve clinical outcomes in spinal fusion surgeries.
The company is actively developing the NELL-1/DBX Fusion Device, which is specifically targeted for use in spinal fusion procedures for skeletally mature patients suffering from degenerative disc disease, particularly at one level from L4-S1. This product represents a significant advancement in the field of spinal surgery, offering potential benefits over existing treatment options through its innovative approach to bone healing and regeneration.
Bone Biologics’ platform technology extends beyond spinal surgery and has potential applications across various surgical specialties. This includes orthopedic surgery, plastic and reconstructive surgery, neurosurgery, interventional radiology, and sports medicine. The versatility of the NELL-1 technology promises enhanced outcomes across a broad range of medical fields by improving bone repair and regeneration.
Founded in 2004 and headquartered in Burlington, Massachusetts, Bone Biologics Corporation has established a strategic license agreement with the UCLA Technology Development Group. This partnership facilitates the development and commercialization of the NELL-1 technology specifically for spinal fusion applications, underscoring the company's commitment to leveraging cutting-edge research to bring innovative solutions to market.
|
